* Drug delivery specialist Core Group plc, of Kilmarnock, Scotland, has signed a marketing and distribution agreement with Schwarz Pharma AG, of Monheim, Germany, for its lead product, Moraxen, which is morphine for rectal delivery in the management of severe pain in terminal cancer patients. Under a 10-year deal that covers the U.K. and Ireland, Core will manufacture and supply Moraxen. Negotiations are continuing with Schwarz for marketing rights in other countries. Financial terms were not disclosed, but the agreement includes minimum sales targets. Schwarz will pay up to 50 percent of the cost of a clinical study, requested by the U.K. Medicines Control Agency as a supplement to Core's submission for marketing authorization. This study is due to be completed by the end of 1998; if it is satisfactory, Schwarz expects to launch Moraxen in 1998.